{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:01:59Z","timestamp":1771002119283,"version":"3.50.1"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/med.0000000000000059","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T15:59:57Z","timestamp":1397663997000},"page":"166-176","source":"Crossref","is-referenced-by-count":21,"title":["Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma"],"prefix":"10.1097","volume":"21","author":[{"given":"Huma Q.","family":"Rana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene R.","family":"Rainville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20211004","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/en.2011-0052","article-title":"Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127.","volume":"152","author":"Jiang","year":"2011","journal-title":"Endocrinology"},{"key":"R2-5-20211004","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"R3-5-20211004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1593\/neo.122132","article-title":"Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.","volume":"15","author":"Shankavaram","year":"2013","journal-title":"Neoplasia (New York, NY)"},{"key":"R4-5-20211004","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.","volume":"105","author":"Jochmanova","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R5-5-20211004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"key":"R6-5-20211004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","article-title":"Von Hippel-Lindau disease.","volume":"2","author":"Kaelin","year":"2007","journal-title":"Ann Rev Pathol"},{"key":"R7-5-20211004","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1210\/jc.2009-0354","article-title":"Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.","volume":"94","author":"Boedeker","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-5-20211004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"R9-5-20211004","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.","volume":"275","author":"Cockman","year":"2000","journal-title":"J Biol Chem"},{"key":"R10-5-20211004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease.","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutat"},{"key":"R11-5-20211004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma.","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"R12-5-20211004","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1210\/jc.2009-0496","article-title":"The approach to the patient with paraganglioma.","volume":"94","author":"Neumann","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-5-20211004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2008-2419","article-title":"Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas andor functional or nonfunctional paragangliomas.","volume":"94","author":"Mannelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-5-20211004","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1210\/jc.2008-2756","article-title":"Genetics of pheochromocytoma and paraganglioma in Spanish patients.","volume":"94","author":"Cascon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-5-20211004","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2008-2504","article-title":"The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.","volume":"94","author":"Burnichon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-5-20211004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","article-title":"Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.","volume":"31","author":"Ricketts","year":"2010","journal-title":"Hum Mutat"},{"key":"R17-5-20211004","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"key":"R18-5-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2012.01.009","article-title":"Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.","volume":"205","author":"Fishbein","year":"2012","journal-title":"Cancer Genet"},{"key":"R19-5-20211004","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-5-20211004","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal andor malignant phaeochromocytomas.","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"key":"R21-5-20211004","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-5-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2796.2009.02111.x","article-title":"SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.","volume":"266","author":"Pasini","year":"2009","journal-title":"J Intern Med"},{"key":"R24-5-20211004","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/hed.23420","article-title":"Unusual case of Cowdenlike syndrome, neck paraganglioma, and pituitary adenoma.","volume":"36","author":"Efstathiadou","year":"2014","journal-title":"Head Neck"},{"key":"R25-5-20211004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1749-6632.2010.05789.x","article-title":"Mendelian genetics of rare -- and not so rare -- cancers.","volume":"1214","author":"Eng","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R26-5-20211004","doi-asserted-by":"crossref","first-page":"E2063","DOI":"10.1210\/jc.2011-1616","article-title":"Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.","volume":"96","author":"Ngeow","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-5-20211004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"R28-5-20211004","first-page":"C33","article-title":"Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II andor Krebs cycle defects Endocr Relat C","volume":"19","author":"Xekouki","year":"2012","journal-title":"ancer"},{"key":"R29-5-20211004","first-page":"E357","article-title":"Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH J Clin Endocrinol M","volume":"97","author":"Xekouki","year":"2012","journal-title":"etab"},{"key":"R30-5-20211004","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma.","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum Mol Genet"},{"key":"R31-5-20211004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/modpathol.2012.153","article-title":"Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors.","volume":"26","author":"Wagner","year":"2013","journal-title":"Mod Pathol"},{"key":"R32-5-20211004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0b013e3182671178","article-title":"Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation.","volume":"37","author":"Miettinen","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R33-5-20211004","doi-asserted-by":"crossref","first-page":"E1472","DOI":"10.1210\/jc.2011-1043","article-title":"SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas.","volume":"96","author":"Korpershoek","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-5-20211004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ejhg.2013.80","article-title":"Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KITPDGFRA wild-type GIST.","volume":"22","author":"Pantaleo","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"R35-5-20211004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00569208","article-title":"Genetic aspects of nonchromaffin paraganglioma.","volume":"60","author":"van Baars","year":"1982","journal-title":"Hum Genet"},{"key":"R36-5-20211004","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","article-title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma.","volume":"325","author":"Hao","year":"2009","journal-title":"Science"},{"key":"R37-5-20211004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"R39-5-20211004","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia.","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"key":"R40-5-20211004","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-5-20211004","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2012-10-460972","article-title":"Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.","volume":"121","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"R42-5-20211004","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.","volume":"99","author":"Buffet","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R43-5-20211004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1HIF2A germline mutation in a congenital polycythemia with paraganglioma.","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med"},{"key":"R44-5-20211004","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma.","volume":"359","author":"Ladroue","year":"2008","journal-title":"N Engl J Med"},{"key":"R45-5-20211004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1677\/ERC-10-0113","article-title":"Mutation analysis of HIF prolyl hydroxylases (PHDEGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.","volume":"18","author":"Astuti","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"R46-5-20211004","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1101\/gad.1648608","article-title":"The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.","volume":"22","author":"Schlisio","year":"2008","journal-title":"Genes Develop"},{"key":"R47-5-20211004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00439-008-0553-1","article-title":"A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors.","volume":"124","author":"Yeh","year":"2008","journal-title":"Hum Genet"},{"key":"R48-5-20211004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/088307380201700802","article-title":"Neurofibromatosis 1: clinical manifestations and diagnostic criteria.","volume":"17","author":"Friedman","year":"2002","journal-title":"J Child Neurol"},{"key":"R49-5-20211004","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2009.11.FOCUS09221","article-title":"Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.","volume":"28","author":"Gottfried","year":"2010","journal-title":"Neurosurg Focus"},{"key":"R51-5-20211004","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2006-2833","article-title":"Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1.","volume":"92","author":"Bausch","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R52-5-20211004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00403-010-1090-z","article-title":"Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects.","volume":"303","author":"Zinnamosca","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"R53-5-20211004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma.","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R54-5-20211004","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R55-5-20211004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2796.1998.00330.x","article-title":"Molecular biology of the MEN2 gene.","volume":"243","author":"Santoro","year":"1998","journal-title":"J Intern Med"},{"key":"R56-5-20211004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2005.15.531","article-title":"RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.","volume":"15","author":"Kouvaraki","year":"2005","journal-title":"Thyroid"},{"key":"R57-5-20211004","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"R58-5-20211004","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.","volume":"98","author":"Thosani","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-5-20211004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2796.2004.01425.x","article-title":"Biochemical diagnosis localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour.","volume":"257","author":"Pacak","year":"2005","journal-title":"J Intern Med"},{"key":"R61-5-20211004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2796.1995.tb01211.x","article-title":"Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group.","volume":"238","author":"Modigliani","year":"1995","journal-title":"J Intern Med"},{"key":"R62-5-20211004","first-page":"89","article-title":"Diagnosis localization and treatment of pheochromocytoma in MEN 2 syndrome.","volume":"43","author":"Ilias","year":"2009","journal-title":"Endocr Regul"},{"key":"R63-5-20211004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"key":"R65-5-20211004","doi-asserted-by":"crossref","first-page":"E805","DOI":"10.1210\/jc.2011-3360","article-title":"TMEM127 screening in a large cohort of patients with pheochromocytoma andor paraganglioma.","volume":"97","author":"Abermil","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-5-20211004","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1001\/jama.2010.1830","article-title":"Spectrum and prevalence of FPTMEM127 gene mutations in pheochromocytomas and paragangliomas.","volume":"304","author":"Yao","year":"2010","journal-title":"JAMA"},{"key":"R67-5-20211004","doi-asserted-by":"crossref","first-page":"E1279","DOI":"10.1210\/jc.2011-0114","article-title":"Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites.","volume":"96","author":"Neumann","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-5-20211004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"R69-5-20211004","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1073\/pnas.0802785105","article-title":"Activation of PI3KAkt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1.","volume":"105","author":"Zhu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R70-5-20211004","doi-asserted-by":"crossref","first-page":"e9084","DOI":"10.1371\/journal.pone.0009084","article-title":"Regulation of gene expression in hepatic cells by the mammalian target of rapamycin (mTOR).","volume":"5","author":"Jimenez","year":"2010","journal-title":"PLoS One"},{"key":"R71-5-20211004","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R72-5-20211004","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1093\/hmg\/ddr376","article-title":"Genomic imprinting at a boundary element flanking the SDHD locus.","volume":"20","author":"Baysal","year":"2011","journal-title":"Human Mol Genet"},{"key":"R73-5-20211004","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbabio.2012.12.005","article-title":"Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors.","volume":"1827","author":"Baysal","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"R74-5-20211004","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbabio.2012.11.005","article-title":"The role of complex II in disease.","volume":"1827","author":"Hoekstra","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"R75-5-20211004","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/jmedgenet-2012-101146","article-title":"Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency.","volume":"49","author":"Alston","year":"2012","journal-title":"J Med Genet"},{"key":"R76-5-20211004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jnnp.2005.067041","article-title":"Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA).","volume":"77","author":"Horvath","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R77-5-20211004","doi-asserted-by":"crossref","first-page":"E2009","DOI":"10.1210\/jc.2011-1244","article-title":"Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect.","volume":"96","author":"Yeap","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R78-5-20211004","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","article-title":"Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.","volume":"41","author":"Gill","year":"2010","journal-title":"Human Pathol"},{"key":"R79-5-20211004","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"key":"R80-5-20211004","doi-asserted-by":"crossref","first-page":"E1248","DOI":"10.1210\/jc.2013-1319","article-title":"A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma.","volume":"98","author":"Rattenberry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R81-5-20211004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cen.12331","article-title":"Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.","volume":"80","author":"McInerney-Leo","year":"2014","journal-title":"Clin Endocrinol"},{"key":"R82-5-20211004","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","article-title":"Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.","volume":"98","author":"Crona","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R83-5-20211004","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ng1641","article-title":"Germline mutations in HRAS proto-oncogene cause Costello syndrome.","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat Genet"},{"key":"R84-5-20211004","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of RasMAPK pathway dysregulation.","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genetics Develop"},{"key":"R85-5-20211004","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-012-1239-y","article-title":"RasMAPK syndromes and childhood hemato-oncological diseases.","volume":"97","author":"Aoki","year":"2013","journal-title":"Int J Hematol"},{"key":"R86-5-20211004","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1210\/jc.2013-2191","article-title":"The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage.","volume":"98","author":"Dahia","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R87-5-20211004","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R88-5-20211004","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin Chem"},{"key":"R89-5-20211004","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators.","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R90-5-20211004","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","article-title":"A comparison of the performance of (6)(8)Ga-DOTATATE PETCT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.","volume":"39","author":"Maurice","year":"2012","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"R92-5-20211004","doi-asserted-by":"crossref","first-page":"E1103","DOI":"10.1210\/jc.2013-1400","article-title":"Familial SDHA mutation associated with pituitary adenoma and pheochromocytomaparaganglioma.","volume":"98","author":"Dwight","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R93-5-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-13-0623","article-title":"Nonpheochromocytoma (PCC)paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.","volume":"170","author":"Papathomas","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R94-5-20211004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association.","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"R95-5-20211004","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2.","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R96-5-20211004","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): diagnosis and management.","volume":"115","author":"Ferner","year":"2013","journal-title":"Handbook Clin Neurol"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201406000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T12:22:41Z","timestamp":1633522961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201406000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0000000000000059","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}